Introduction: Antimalarial drug resistance threatens the efficacy of artemisinin combination therapies (ACTs), the first-line treatment for Plasmodium falciparum malaria. Standard ACTs combine a fast-acting artemisinin derivative with a single long-acting partner drug, whereas novel triple artemisinin combination therapies (TACTs) co-administer two long-acting partner drugs. Recent clinical trials of TACTs demonstrate favourable tolerability and high efficacy […]
Author: MTully
Evaluation of a pharmacokinetic-pharmacodynamic model for predicting parasitological outcomes in Phase 2 studies of new antimalarial drugs
Introduction: The rise of multidrug resistant malaria demands the urgent development of novel antimalarial compounds. For a drug to achieve registration and availability in the market, new treatments must undergo a series of rigorous evaluations, from preclinical studies in human volunteers experimentally infected with malaria, through to Phase 3 clinical trials in malaria patients. Pharmacokinetic-pharmacodynamic […]